Understanding Metastatic Breast Cancer

The number of metastatic sites is associated with more aggressive MBC1,2

  • Patients with metastatic breast cancer who present metastases at ≥3 sites are likely to have a comparatively less favorable outcome than those with ≤2 metastatic sites
  • There is lower median survival time for patients with increasing number of metastatic sites1a
aUnivariate survival analysis from a retrospective database of 1430 patients from 8 consecutive prospective trials conducted between 1977 and 1992 of anthracycline-based first-line chemotherapy in MBC.

Understanding Metastatic Breast Cancer

The number of metastatic sites is associated with more aggressive MBC1,2

  • Patients with metastatic breast cancer who present metastases at ≥3 sites are likely to have a comparatively less favorable outcome than those with ≤2 metastatic sites
  • There is lower median survival time for patients with increasing number of metastatic sites1a
aUnivariate survival analysis from a retrospective database of 1430 patients from 8 consecutive prospective trials conducted between 1977 and 1992 of anthracycline-based first-line chemotherapy in MBC.

INDICATION

ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

INDICATION

ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.